[Clinical experience with sustained release cefalexin (author's transl)].
S-6436 and S-6437 are preparations of sustained release cefalexin, which consist of 30% of nonenteric coated granules and 70% of enteric coated ones. With oral administration of those preparations at b.i.d. regimen, good efficacies can be expected. Those preparations were orally given to 39 patients with skin and soft tissue infections and 4 patients with other infections at the dose levels of 1,000 approximately 2,000 mg/day (20 approximately 50 mg/day in children) at 2 divided doses. Excellent effect was observed in 30 patients and good effect was found in 13 patients. In 11 patients, usefulness of b.i.d. regimen was recognized. No side effects were observed. From the above. S-6436 and S-6437 are considered to be unique and useful preparations.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy / Q000382:microbiology; D002506:Cephalexin / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D003692:Delayed-Action Preparations; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged
D003692:Delayed-Action Preparations; D002506:Cephalexin